Mariana Ferreira
Overview
Explore the profile of Mariana Ferreira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Von Schreeb S, Ricoca Peixoto V, Firme A, Ferreira M, Lourenco Silva R, Vasconcelos P
Acta Med Port
. 2024 Oct;
37(10):744-745.
PMID: 39366368
No abstract available.
12.
Ferreira M, Carvalho V, Ribeiro J, Lima R, Teixeira S, Pinho D
Micromachines (Basel)
. 2024 Jul;
15(7).
PMID: 39064385
The evolution in the biomedical engineering field boosts innovative technologies, with microfluidic systems standing out as transformative tools in disease diagnosis, treatment, and monitoring. Numerical simulation has emerged as a...
13.
Santos-Rocha R, Ferreira M, Pimenta N, Branco M, Oviedo-Caro M, Szumilewicz A
Healthcare (Basel)
. 2024 Jun;
12(11).
PMID: 38891196
Health and exercise technology may promote a healthy lifestyle during pregnancy. The objective of this cross-sectional study was to understand and involve the perspective of pregnant women as users in...
14.
Dias-Carvalho A, Ferreira M, Reis-Mendes A, Ferreira R, Bastos M, Fernandes E, et al.
Heliyon
. 2024 Jun;
10(11):e31608.
PMID: 38868005
Doxorubicin (DOX) is an anthracycline used to treat a wide range of tumours. Despite its effectiveness, it is associated with a long range of adverse effects, of which cognitive deficits...
15.
Ferreira M, Carneiro P, Costa V, Carvalho F, Meisel A, Capela J
Rev Neurosci
. 2024 Jun;
35(7):709-746.
PMID: 38843463
The prevalence of stroke and traumatic brain injury is increasing worldwide. However, current treatments do not fully cure or stop their progression, acting mostly on symptoms. Amphetamine and methylphenidate are...
16.
Carneiro P, Ferreira M, Costa V, Carvalho F, Capela J
Curr Res Toxicol
. 2024 Apr;
6:100165.
PMID: 38562456
Full treatment of the second most common neurodegenerative disorder, Parkinson's disease (PD), is still considered an unmet need. As the psychostimulants, amphetamine (AMPH) and methylphenidate (MPH), were shown to be...
17.
Reis-Mendes A, Vitorino-Oliveira C, Ferreira M, Carvalho F, Remiao F, Sousa E, et al.
Cardiovasc Toxicol
. 2024 Feb;
24(3):266-279.
PMID: 38347287
Doxorubicin (DOX; also known as adriamycin) serves as a crucial antineoplastic agent in cancer treatment; however, its clinical utility is hampered by its' intrinsic cardiotoxicity. Although most DOX biotransformation occurs...
18.
Vale-Costa S, Etibor T, Bras D, Sousa A, Ferreira M, Martins G, et al.
PLoS Biol
. 2023 Nov;
21(11):e3002290.
PMID: 37983294
It is now established that many viruses that threaten public health establish condensates via phase transitions to complete their lifecycles, and knowledge on such processes may offer new strategies for...
19.
Reis-Mendes A, Ferreira M, Padrao A, Duarte J, Duarte-Araujo M, Remiao F, et al.
Inflammation
. 2023 Oct;
47(1):264-284.
PMID: 37833616
Doxorubicin (DOX) is a topoisomerase II inhibitor used in cancer therapy. Despite its efficacy, DOX causes serious adverse effects, such as short- and long-term cardiotoxicity. This work aimed to assess...
20.
Reis-Mendes A, Ferreira M, Duarte J, Duarte-Araujo M, Remiao F, Carvalho F, et al.
Arch Toxicol
. 2023 Sep;
97(12):3163-3177.
PMID: 37676301
Doxorubicin (DOX) is a potent chemotherapeutic agent used against several cancer types. However, due to its cardiotoxic adverse effects, the use of this drug may be also life-threatening. Although most...